CAR T-Cell Therapy

A phase 2 trial is planned for an allogeneic CAR T-cell product in patients with lung or breast cancer with brain metastases.

Published phase 1 findings support the promising efficacy and tolerability of anito-cel in relapsed/refractory multiple myeloma, explains lead author Matthew Frigault, MD.

In the pivotal phase 2 QUINTESSENTIAL trial, arlo-cel, a GPRC5D-targeted CAR T-cell therapy, showed favorable overall response rate in patients who had received multiple prior lines including BCMA-targeted therapy.

The study also identified a link between early fatigue and eventual response to CAR T.

FDA clears IND for ADI-212, an off-the-shelf PSMA-targeted gamma-delta CAR T for metastatic castration-resistant prostate cancer, as phase 1/2 trial readies 2026 enrollment.

Explore how REMS removal streamlines CAR T-cell access in second-line DLBCL, plus smart bridging options and who qualifies when relapse strikes fast.

FDA grants designations to off-the-shelf CD19 CAR T cema-cel for MRD+ LBCL consolidation, as ALPHA3 data show strong MRD clearance with outpatient care.

Experts break down second-line CAR T for relapsed DLBCL—who qualifies, what to expect, and why logistics still block access.

Phase 1 TRAVERSE results show that off-the-shelf CD70 CAR T ALLO-316 drives durable responses in refractory clear cell kidney cancer, with manageable safety signals.

During a live event, Prerna Mewawalla, MD, discussed the choice between bispecific antibody therapy and CAR T-cell therapy in myeloma as both therapies have been introduced earlier in sequence.

During a live event, Syed Abbas Ali, MBBS, and participants discussed treatment selection for a patient who has not yet received BCMA-targeted therapy after a second relapse of multiple myeloma.

Results from the SPEARHEAD-1 trial supported FDA approval of the engineered T-cell product for patients as young as 12 years of age.

During a live event, Prerna Mewawalla, MD, and participants discussed selecting therapy for patients with early relapsed/refractory multiple myeloma who are not candidates for CAR T-cell therapy.

At the EHA 2026 Congress, researchers presented novel treatments and combinations for newly diagnosed multiple myeloma, relapsed disease, and smoldering myeloma.